Table 4.

Analysis of laboratory and clinical outcomes in combined data from the University of Ibadan, UIC, and Walk-PHaSST cohorts

	N	High risk	N	Standard risk	P*
WBC count, × 103/µL	329	10.7 (8.5-13.5)	567	10.2 (8.2-12.6)	.049
Hemoglobin, g/dL	329	8.2 (7.2-9.3)	567	8.5 (7.5-9.5)	.0055
Reticulocyte, %	259	11.5 (7.9-16.7)	434	9.6 (6.2-13.9)	1.0 × 10−5
VOCs ≥3/y, n (%)	329	181 (55)	567	306 (54)	.3
Stroke history, n (%)	329	57 (17)	567	53 (9)	.0002

Values are expressed as medians and IQRs.

^*P value adjusted for age, sex, hydroxyurea therapy, and site by using linear and logistic regression analysis.